PTAB refuses to sanction Bass, Spangenberg calls for crowdsourcing of IPRs
In a busy week for hedge fund IPR news, the PTAB has refused to sanction Kyle Bass’s Coalition for Affordable Drugs but denied an IPR petition by Ferrum Ferro Capital, while Erich Spangenberg has urged crowdsourcing of IPRs against pharma companies
The Patent Trial and Appeal Board (PTAB) has refused Celgene’s motion for sanctions against Kyle Bass’s Coalition for Affordable Drugs in the inter partes review (IPR) petitions launched against its Thalomid and Revlamid patents.
In its order denying...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.